External Quality Assurance (EQA) Program

for

G6PD Quantitative Test in Philippines


Notes
 

TAF_Logo_v3.jpg

 

2018 External Quality Assurance (EQA) Program for G6PD Quantitative Test in Philippines  [EQA Survey Schedule for 2018]

Application Form for Changing Data in G6PD EQA MIS System

 


G6PD EQA MIS System [login]

FAQ : [website security certificate Problem]

[EQA for G6PD in Taiwan]


Introduction

  Glucose-6-phosphate dehydrogenase (G6PD; EC1.1.1.49; MIM305900) deficiency is the most common enzymopathic in humans. A relatively high incidence (>2%) of this enzymopathy, which may cause of neonatal jaundice and acute hemolytic anemia, was found in Southeast Asia. If it is not prevented or treated properly, neonatal jaundice may lead to kernicterus and cause death or permanent neurological damage. The life-threatening hemolytic crises that occur later may cause permanent kidney damage and can be induced by certain drugs or by eating fava beans. In order to reduce these complications, neonatal screening for G6PD deficiency has been carried out in many countries in this region.

  In order to assure the reliability and consistence of the G6PD neonatal screening and confirmatory tests among different laboratories, an external qaulity assurance (EQA) program for screening G6PD activity in neonatal dried blood spots and determination of G6PD activity in hemolysate has been carried out in Taiwan since 1988 and adopted by the Philippines neonatal screening program (Screening test since 1999). 

  For the EQA survey on the confirmatory quantitative test (determination of G6PD activity in hemolysate), periodically, three lyophilized QC materials were sent to each participating laboratory on dry ice by speed post delivery. The results of G6PD activity analysis were requested to be returned by facsimile and submitted by internet within 8 days. The external QA results were evaluated and compared to the median of all reports received and the reference value determined by the reference laboratory. The summary report for each survey was published on website within two weeks after the survey started. 

 

Instruction to External Quality Assurance (EQA) for G6PD Quantitative Test

 

Participating Laboratories

[Angeles University Foundation Medical Center] [Batangas Regional Hospital] [Brent Hospital & Colleges Incorporated]
[Cagayan Valley Medical Center] [Cebu Doctors' University Hospital] [Davao Medical School Foundation, Inc.]
[Dr. Pablo O. Torre Memorial Hospital] [Eastern Visayas Regional Medical Center] [General Santos Doctors' Hospital]
[Ilocos Training and Regional Medical Center, Department of Laboratories] [Kidapawan Doctors Hospital, Inc.] [La Vina General Hospital Inc]
[Lipa Medix Medical Center] [Luna Goco Medical Center] [Makati Medical Center - Department of Pathology and Laboratories]
[Mariano Marcos Memorial Hospital And Medical Center] [Mayor Hilarion A Ramiro Sr. Training and Teaching Hospital] [MCU-FDTMF Hospital]
[Our Lady of Lourdes Hospital] [Polymedic Medical Plaza] [Region 1 Medical Center]
[Tagum Doctors Hospital] [The Medical City] [University of Perpetaul Help Dalta Medical Center]
[UPH-Dr. Jose G.Tamayo Medical Center]  

 

 

Results :

  Jan 2018 ~

      1.Survey No : RH2018-01 ( IMP ) ( PDF )

      2.Survey No : RH2018-02 ( PDF )

 

January 2017 ~ December 2017          

January 2016 ~ December 2016          

January 2015 ~ December 2015

January 2014 ~ December 2014          

January 2013 ~ December 2013          

January 2012 ~ December 2012          

January 2011 ~ December 2011          

January 2010 ~ December 2010

June 2009 ~ December 2009


[ Home ]

Newborn Screening QA Program

Preventive Medicine Foundation

Newborn Screening Reference Center

National Institutes of Health

P.O. Box 624, Taipei Xinwei, Taiwan 10699 University of the Philippines Manila  
Tel : + 886-2-2703-6080;  Fax : +886-2-2703-6070  

Unit 104, Building A, UP Ayala Land Technohub, Brgy. UP Campus,
Diliman, Quezon City 1101, Philippines

 
  Fax : + 632-351-7903;  
         
updated : 07 May, 2018